重复:N Engl J Med:脓毒血症快速治疗能否赢得更多的生存机会?

2017-07-19 选题审校:应颖秋 编辑:贾朝娟 环球医学

有关脓毒血症的快速治疗是否能改善患者结局,仍有争议。2017年6月,发表在《N Engl J Med》的一项研究显示,较快完成3 h集束化脓毒血症治疗和快速给予抗生素与风险校正的较低院内死亡率相关。

有关脓毒血症的快速治疗是否能改善患者结局,仍有争议。2017年6月,发表在《N Engl J Med》的一项研究显示,较快完成3 h集束化脓毒血症治疗和快速给予抗生素与风险校正的较低院内死亡率相关。

背景:2013年,纽约开始要求医院遵守脓毒血症早期诊断和治疗的管理方案。但是,有关脓毒血症的快速治疗是否能改善患者结局,仍有争议。

方法:研究者研究了2014年4月1日至2016年6月30日间纽约州卫生部报告的脓毒血症和感染性休克的数据。患者在到达争诊室后6 h内开始脓毒血症管理方案,并在12 h内完成脓毒血症患者3 h集束化治疗的所有项目(例如,血培养、广谱抗生素和乳酸水平检测)。采用多水平模型评估3 h集束完成时间和校正风险的死亡率之间的关联。研究者还考察了抗生素给药时间和首剂静脉输液的时间。

结果:在149家医院的49331名患者中,40696名(82.5%)在3 h内完成3 h集束化治疗。完成3 h集束化治疗的中位时间是1.30 h(四分位间距,0.65~2.35),抗生素给药的中位时间是0.95 h(四分位间距,0.35~1.95),完成输液的中位时间是2.56 h(四分位间距,1.33~4.20)。在12 h完成3 h集束化治疗的患者中,较长时间完成集束化治疗与较高的风险校正院内死亡率相关(比值比,1.05/h;95%置信区间[CI],1.02~1.05;P<0.001),与较长的抗生素给药时间(比值比,1.04/h;95%CI,1.03~1.06;P<0.001)也相关,但与较长完成静脉输液的时间无关(比值比,1.01/h;95%CI,0.99~1.02;P=0.21)。

结论:较快完成3 h集束化脓毒血症治疗和快速给予抗生素与风险校正的较低院内死亡率相关,但快速完成首剂静脉输液与之无关。

原始出处:
Seymour, C. W., et al. (2017). "Time to Treatment and Mortality during Mandated Emergency Care for Sepsis." N Engl J Med 376(23): 2235-2244.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2081389, encodeId=b0db20813898d, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Dec 23 17:44:00 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785477, encodeId=40561e8547710, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Mon Apr 16 07:44:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607845, encodeId=f7dc160e845a7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 21 13:44:00 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224411, encodeId=1c7522441166, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KiblTyxD95ExbzUoCVcRuhPibXboL28wicFMTXUhCA0RWCyQZYC5Na3ap7CxjialMkB50VEJ0XToQQTC/0, createdBy=470c1945776, createdName=方舒, createdTime=Thu Jul 20 22:22:37 CST 2017, time=2017-07-20, status=1, ipAttribution=)]
    2017-12-23 spoonycyy
  2. [GetPortalCommentsPageByObjectIdResponse(id=2081389, encodeId=b0db20813898d, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Dec 23 17:44:00 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785477, encodeId=40561e8547710, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Mon Apr 16 07:44:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607845, encodeId=f7dc160e845a7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 21 13:44:00 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224411, encodeId=1c7522441166, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KiblTyxD95ExbzUoCVcRuhPibXboL28wicFMTXUhCA0RWCyQZYC5Na3ap7CxjialMkB50VEJ0XToQQTC/0, createdBy=470c1945776, createdName=方舒, createdTime=Thu Jul 20 22:22:37 CST 2017, time=2017-07-20, status=1, ipAttribution=)]
    2018-04-16 haouestc
  3. [GetPortalCommentsPageByObjectIdResponse(id=2081389, encodeId=b0db20813898d, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Dec 23 17:44:00 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785477, encodeId=40561e8547710, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Mon Apr 16 07:44:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607845, encodeId=f7dc160e845a7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 21 13:44:00 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224411, encodeId=1c7522441166, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KiblTyxD95ExbzUoCVcRuhPibXboL28wicFMTXUhCA0RWCyQZYC5Na3ap7CxjialMkB50VEJ0XToQQTC/0, createdBy=470c1945776, createdName=方舒, createdTime=Thu Jul 20 22:22:37 CST 2017, time=2017-07-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2081389, encodeId=b0db20813898d, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Dec 23 17:44:00 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785477, encodeId=40561e8547710, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Mon Apr 16 07:44:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607845, encodeId=f7dc160e845a7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 21 13:44:00 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224411, encodeId=1c7522441166, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KiblTyxD95ExbzUoCVcRuhPibXboL28wicFMTXUhCA0RWCyQZYC5Na3ap7CxjialMkB50VEJ0XToQQTC/0, createdBy=470c1945776, createdName=方舒, createdTime=Thu Jul 20 22:22:37 CST 2017, time=2017-07-20, status=1, ipAttribution=)]
    2017-07-20 方舒

    学习

    0

相关资讯

Sci Adv:MTA可能用于预测脓毒症患者死亡风险

最近,杜克大学的科学家发现了一种标志物可用以提升脓毒血症的早期诊断和治疗,改善患者预后,从而挽救患者的生命。这种标志物是一种叫作甲硫腺苷的小分子(methylthioadenosine,MTA),它能预测哪个病人最有可能因脓毒血症而死亡。

Crit Care Med:退热治疗能否降低脓毒血症成年患者的28日死亡率

2017年5月,发表在《Crit Care Med》上的一项荟萃分析考察了退热疗法对危重脓毒血症成人死亡率的影响。研究结果显示,退热治疗不会显着改善脓毒血症成年患者的28日/医院死亡率。

Crit Care Med:降钙素原水平可预测脓毒血症患者28日全因死亡率

当严重细菌、真菌、寄生虫感染以及脓毒症和多脏器功能衰竭时降钙素原在血浆中的水平升高。2017年5月,发表在《Crit Care Med》的一项研究调查了降钙素原水平是否可预测严重脓毒血症患者的死亡率。

Crit Care Med:ICU脓毒血症患者住院前口服糖皮质激素与ARDS风险降低相关

糖皮质激素一直广泛用于治疗急性呼吸窘迫综合征。2017年5月,发表在《Crit Care Med》的一项研究显示,在ICU脓毒血症患者中,住院前口服糖皮质激素与较低的早期急性呼吸窘迫综合征发生率单独相关。

Crit Care Med:脓毒血症患者的抗生素治疗

近期,一篇发表在Crit Care Med杂志上的文章就临床医师启动抗生素治疗脓毒血症的时间进行了研究,旨在进行临床治疗的规范,提高脓毒血症治疗的有效性。我们都知道,较晚的抗生素治疗启动与脓毒血症的较高的病死率相关。该研究选取了2009-2015年期间的就诊于急诊科的严重性难治脓毒血症及脓毒血症休克的患者作为研究对象。研究者使用多重线性回归的方法,评估主治医师的治疗与抗生素治疗时机的关系。通过对疾

Crit Care Med:肥胖的危重脓毒血症患者常规哌拉西林剂量有无不足或过量?

肥胖和危重疾病会改变抗生素的药代动力学,那么肥胖的危重脓毒血症患者使用常规剂量哌拉西林-他唑巴坦是否面临着剂量不足或给药过量的风险?2017年5月,发表在《Crit Care Med》的一项研究显示,使用常规剂量的16 g/2 g/24 h持续输注,当面对MIC较高的病原体时,肥胖患者比非肥胖患者更可能经历哌拉林剂量不足。